199 related articles for article (PubMed ID: 30132520)
1. COL1A1: A potential therapeutic target for colorectal cancer expressing wild-type or mutant KRAS.
Zhang Z; Fang C; Wang Y; Zhang J; Yu J; Zhang Y; Wang X; Zhong J
Int J Oncol; 2018 Nov; 53(5):1869-1880. PubMed ID: 30132520
[TBL] [Abstract][Full Text] [Related]
2. LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer.
Vakana E; Pratt S; Blosser W; Dowless M; Simpson N; Yuan XJ; Jaken S; Manro J; Stephens J; Zhang Y; Huber L; Peng SB; Stancato LF
Oncotarget; 2017 Feb; 8(6):9251-9266. PubMed ID: 27999210
[TBL] [Abstract][Full Text] [Related]
3. SLC25A22 Promotes Proliferation and Survival of Colorectal Cancer Cells With KRAS Mutations and Xenograft Tumor Progression in Mice via Intracellular Synthesis of Aspartate.
Wong CC; Qian Y; Li X; Xu J; Kang W; Tong JH; To KF; Jin Y; Li W; Chen H; Go MY; Wu JL; Cheng KW; Ng SS; Sung JJ; Cai Z; Yu J
Gastroenterology; 2016 Nov; 151(5):945-960.e6. PubMed ID: 27451147
[TBL] [Abstract][Full Text] [Related]
4. BRAF, PIK3CA, and HER2 Oncogenic Alterations According to KRAS Mutation Status in Advanced Colorectal Cancers with Distant Metastasis.
Nam SK; Yun S; Koh J; Kwak Y; Seo AN; Park KU; Kim DW; Kang SB; Kim WH; Lee HS
PLoS One; 2016; 11(3):e0151865. PubMed ID: 26991109
[TBL] [Abstract][Full Text] [Related]
5. Radioresistance of KRAS/TP53-mutated lung cancer can be overcome by radiation dose escalation or EGFR tyrosine kinase inhibition in vivo.
Gurtner K; Kryzmien Z; Koi L; Wang M; Benes CH; Hering S; Willers H; Baumann M; Krause M
Int J Cancer; 2020 Jul; 147(2):472-477. PubMed ID: 31359406
[TBL] [Abstract][Full Text] [Related]
6. TIMP-1 is under regulation of the EGF signaling axis and promotes an aggressive phenotype in KRAS-mutated colorectal cancer cells: a potential novel approach to the treatment of metastatic colorectal cancer.
Tarpgaard LS; Ørum-Madsen MS; Christensen IJ; Nordgaard C; Noer J; Guren TK; Glimelius B; Sorbye H; Ikdahl T; Kure EH; Tveit KM; Nielsen HJ; Pfeiffer P; Brünner N; Moreira JM
Oncotarget; 2016 Sep; 7(37):59441-59457. PubMed ID: 27509063
[TBL] [Abstract][Full Text] [Related]
7. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.
László L
Magy Onkol; 2010 Dec; 54(4):383-94. PubMed ID: 21163770
[TBL] [Abstract][Full Text] [Related]
8. Comparison of neuroendocrine differentiation and KRAS/NRAS/BRAF/PIK3CA/TP53 mutation status in primary and metastatic colorectal cancer.
Kleist B; Kempa M; Novy M; Oberkanins C; Xu L; Li G; Loland C; Poetsch M
Int J Clin Exp Pathol; 2014; 7(9):5927-39. PubMed ID: 25337237
[TBL] [Abstract][Full Text] [Related]
9. KRAS mutations in non-small-cell lung cancer and colorectal cancer: implications for EGFR-targeted therapies.
Maus MK; Grimminger PP; Mack PC; Astrow SH; Stephens C; Zeger G; Hsiang J; Brabender J; Friedrich M; Alakus H; Hölscher AH; Lara P; Danenberg KD; Lenz HJ; Gandara DR
Lung Cancer; 2014 Feb; 83(2):163-7. PubMed ID: 24331409
[TBL] [Abstract][Full Text] [Related]
10. Cetuximab-mediated ADCC activity is correlated with the cell surface expression level of EGFR but not with the KRAS/BRAF mutational status in colorectal cancer.
Seo Y; Ishii Y; Ochiai H; Fukuda K; Akimoto S; Hayashida T; Okabayashi K; Tsuruta M; Hasegawa H; Kitagawa Y
Oncol Rep; 2014 May; 31(5):2115-22. PubMed ID: 24626880
[TBL] [Abstract][Full Text] [Related]
11. BMP4 and PHLDA1 are plausible drug-targetable candidate genes for KRAS G12A-, G12D-, and G12V-driven colorectal cancer.
Ohnami S; Maruyama K; Chen K; Takahashi Y; Hatakeyama K; Ohshima K; Shimoda Y; Sakai A; Kamada F; Nakatani S; Naruoka A; Ohnami S; Kusuhara M; Akiyama Y; Kagawa H; Shiomi A; Nagashima T; Urakami K; Yamaguchi K
Mol Cell Biochem; 2021 Sep; 476(9):3469-3482. PubMed ID: 33982211
[TBL] [Abstract][Full Text] [Related]
12. GATA binding protein 2 overexpression is associated with poor prognosis in KRAS mutant colorectal cancer.
Xu K; Wang J; Gao J; Di J; Jiang B; Chen L; Wang Z; Wang A; Wu F; Wu W; Shen L; Su X
Oncol Rep; 2016 Sep; 36(3):1672-8. PubMed ID: 27460045
[TBL] [Abstract][Full Text] [Related]
13. Identification of
Zhang M; Wang HZ; Li HO; Zhou YJ; Peng RY; Liu J; Zhao Q
DNA Cell Biol; 2020 Sep; 39(9):1639-1648. PubMed ID: 32552000
[TBL] [Abstract][Full Text] [Related]
14. Clinical Role of ASCT2 (SLC1A5) in KRAS-Mutated Colorectal Cancer.
Toda K; Nishikawa G; Iwamoto M; Itatani Y; Takahashi R; Sakai Y; Kawada K
Int J Mol Sci; 2017 Jul; 18(8):. PubMed ID: 28749408
[TBL] [Abstract][Full Text] [Related]
15. Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations.
Lee J; Lee I; Han B; Park JO; Jang J; Park C; Kang WK
J Natl Cancer Inst; 2011 Apr; 103(8):674-88. PubMed ID: 21398618
[TBL] [Abstract][Full Text] [Related]
16. Investigation of FIH-1 and SOCS3 expression in KRAS mutant and wild-type patients with colorectal cancer.
Vakil L; Najafipour R; Rakhshani N; Zamani F; Morakabati A; Javadi A
Tumour Biol; 2016 Jul; 37(7):8841-8. PubMed ID: 26749281
[TBL] [Abstract][Full Text] [Related]
17. Dual role of sprouty2 as an inhibitor of RAS/ERK-driven proliferation and a promoter of cancer invasion in KRAS wild-type colorectal cancer.
Lee CT; Chu CA; Wang YM; Wang YW; Chen YL; Ho CL; Yeh YM; Lin PC; Lin BW; Chen PC; Chen SH; Chan RH; Chang C; Chow NH
Mol Carcinog; 2023 Jul; 62(7):951-962. PubMed ID: 37014154
[TBL] [Abstract][Full Text] [Related]
18. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
Di Nicolantonio F; Martini M; Molinari F; Sartore-Bianchi A; Arena S; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A
J Clin Oncol; 2008 Dec; 26(35):5705-12. PubMed ID: 19001320
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of wild-type p21Ras plays a prominent role in colorectal cancer.
Bai S; Feng Q; Pan XY; Zou H; Chen HB; Wang P; Zhou XL; Hong YL; Song SL; Yang JL
Int J Mol Med; 2017 Apr; 39(4):861-868. PubMed ID: 28259994
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the prevalence of KRAS-LCS6 polymorphism (rs61764370) within different tumour types (colorectal, breast, non-small cell lung cancer and brain tumours). A study of the Czech population.
Uvirova M; Simova J; Kubova B; Dvorackova N; Tomaskova H; Sedivcova M; Dite P
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2015 Sep; 159(3):466-71. PubMed ID: 26077004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
